5. Conclusions
PD
There is an unmet clinical need for a GnRH antagonist that has improved local tolerability and a sustained duration of action. Teverelix DP has the potential to address both of these points. Good local tolerability has been evidenced in numerous clinical trials, and data reported from two regimens with mean periods of castration of 55.32 days and 68.95 days, respectively, suggest that an injection interval of 6+ weeks may be a possibility. PK and PD modelling of existing data plus further clinical trials to test loading and maintenance doses will be required. 